Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith, M Hidalgo… - Investigational new …, 2006 - Springer
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …
被引用次数：98 相关文章

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.

J Li, J Brahmer, W Messersmith, M Hidalgo… - Investigational new …, 2006 - europepmc.org
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

[引用][C] Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith, M Hidalgo… - Investigational New …, 2006 - cir.nii.ac.jp
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma
proteins and blood cells: in vitro and in cancer patients | CiNii Research CiNii 国立情報学 …

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: In vitro and in cancer patients

J Li, J Brahmer, W Messersmith… - Investigational …, 2006 - pure.johnshopkins.edu
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith, M Hidalgo… - Investigational New …, 2006 - infona.pl
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith… - Investigational New …, 2006 - search.proquest.com
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith… - Investigational …, 2006 - pubmed.ncbi.nlm.nih.gov
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: In vitro and in cancer patients

J Li, J Brahmer, W Messersmith… - Investigational …, 2006 - ohiostate.elsevierpure.com
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

[引用][C] Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J LI - Invest New Drugs, 2006 - cir.nii.ac.jp
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma
proteins and blood cells : in vitro and in cancer patients | CiNii Research CiNii 国立情報学 …

[引用][C] Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

J Li, J Brahmer, W Messersmith, M Hidalgo… - Investigational new …, 2006 - Springer